Tencentriq was granted accelerated approval for use in combination with paclitaxel protein-bound for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 on March 8, 2019.
The indication is approved under accelerated approval based on progression-free survival and continued approval may be contingent on verification and description of clinical benefit in confirmatory trials, according to the FDA.
CSI is one of the first reference laboratories to offer the new companion test.
The new assay is used to determine PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area.
CSI Laboratories is a specialised cancer diagnostics laboratory focused specifically on meeting the unique needs and challenges of pathologists and community hospitals.
CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization, immunohistochemistry, molecular genetics, and consultations in the areas of hematopathology and surgical pathology.
CSI Laboratories is a CLIA-certified and CAP-accredited laboratory located in Alpharetta, GA.
CSI Laboratories is independently owned and operated by medical professionals and has provided expert diagnostic testing to pathologists across the United States since 1997.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886